Erythropoietin does not increase the frequency of thromboembolic events or hepatocellular carcinoma in hepatitis C patients treated with combination antiviral therapy

Juan F. Gallegos-Orozco, Kristina T. Werner, Marianne Rosati, Thomas J. Byrne, Vijayan Balan, Hugo E. Vargas, Jorge Rakela

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Erythropoietin does not increase the frequency of thromboembolic events or hepatocellular carcinoma in hepatitis C patients treated with combination antiviral therapy'. Together they form a unique fingerprint.